Immuron Limited (IMRN): Price and Financial Metrics


Immuron Limited (IMRN): $2.02

0.02 (+1.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

IMRN Stock Summary

  • For IMRN, its debt to operating expenses ratio is greater than that reported by only 0.51% of US equities we're observing.
  • With a year-over-year growth in debt of -100%, IMMURON LTD's debt growth rate surpasses just 0% of about US stocks.
  • Revenue growth over the past 12 months for IMMURON LTD comes in at -70.87%, a number that bests just 2.37% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to IMRN, based on their financial statements, market capitalization, and price volatility, are UG, ORGO, CETX, DDI, and MGIC.
  • Visit IMRN's SEC page to see the company's official filings. To visit the company's web site, go to www.immuron.com.au.

IMRN Stock Price Chart Interactive Chart >

Price chart for IMRN

IMRN Price/Volume Stats

Current price $2.02 52-week high $4.40
Prev. close $2.00 52-week low $1.69
Day low $2.02 Volume 1,400
Day high $2.10 Avg. volume 268,216
50-day MA $2.02 Dividend yield N/A
200-day MA $2.58 Market Cap 11.50M

Immuron Limited (IMRN) Company Bio


Immuron Limited focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company was founded in 1994 and is based in Australia.


IMRN Latest News Stream


Event/Time News Detail
Loading, please wait...

IMRN Latest Social Stream


Loading social stream, please wait...

View Full IMRN Social Stream

Latest IMRN News From Around the Web

Below are the latest news stories about IMMURON LTD that investors may wish to consider to help them evaluate IMRN as an investment opportunity.

Immuron completes strategic investment in leading gut health biotech Ateria Health

Highlights: Immuron has completed settlement of strategic investment in leading gut health biotech Ateria Health, in accordance with signed subscription and option agreement (announced 13 October 2022): Strategic investment of approximately £1.5m (A$2.6m) to acquire an initial 17.5% of Ateria Health; Option for further investment of £1.47m, expiring on 31 July 2023 Ateria Health is a U.K. based biotech company that develops and distributes supplements for overall health, including products that

Yahoo | November 16, 2022

Immuron CEO, Steven Lydeamore to present at AusBioInvest

MELBOURNE, Australia, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases; is pleased to provide investors with a copy of the presentation slide deck to be showcased at AusBioInvest 2022 in Perth, Australia on October 27, 2022, by our Chief Executive Officer, Steven Lydeamore. A copy

Yahoo | October 26, 2022

Immuron Announces Strategic Investment In UK-Based Gut Health Company

Immuron Limited (NASDAQ: IMRN) signed a strategic investment and option agreement with Ateria Health Limited for an upfront cash investment of £1.48 million. The company has also announced a strategic investment of approximately £1.5 million (A$2.6 million) to acquire an initial 17.5% of Ateria Health. Potential adjustment to share percentage for Immuron dependent on Ateria's performance during its CY2023. Ateria Health Ltd is a U.K.-based health and wellness company that has developed a novel i

Yahoo | October 13, 2022

Immuron strategic investment in leading gut health biotech Ateria Health

Highlights: Immuron has signed a subscription and option agreement with leading gut health biotech Ateria Health: Strategic investment of approximately £1.5m (A$2.6m) to acquire an initial 17.5% of Ateria Health; Option for further investment of £1.47m, expiring on 31 July 2023 Ateria Health is a U.K. based biotech company that develops and distributes supplements for overall health, including products that strengthen the gut microbiome. Ateria has developed and recently launched a ground-breaki

Yahoo | October 13, 2022

Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron

Highlights: Clinical Trial Master Service Agreement with US-based Pharmaron ExecutedInvestigational New Drug (IND) application to be submitted to the U.S. Food and Drug administration (FDA)Plans in place to initiate a Controlled Human Infection Model (CHIM) clinical trial in 60 healthy volunteers in the USAClinical Trial to examine a dosing regimen for Travelan more suited for use by the US militaryInfectious diarrhea is the most common illness reported by travelers MELBOURNE, Australia, Oct. 04

Yahoo | October 4, 2022

Read More 'IMRN' Stories Here

IMRN Price Returns

1-mo 11.25%
3-mo N/A
6-mo -30.82%
1-year -33.66%
3-year -48.86%
5-year -58.52%
YTD -19.20%
2021 -60.75%
2020 75.48%
2019 N/A
2018 0.00%
2017 N/A

Continue Researching IMRN

Want to see what other sources are saying about Immuron Ltd's financials and stock price? Try the links below:

Immuron Ltd (IMRN) Stock Price | Nasdaq
Immuron Ltd (IMRN) Stock Quote, History and News - Yahoo Finance
Immuron Ltd (IMRN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8233 seconds.